Barclays
KYNB

Barclays’s Kyntra Bio KYNB Stock Holding History

Barclays’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Hold
0
– – – 5360
2025
Q1 		– Hold
0
– – – 5353
2024
Q4 		– Hold
0
– – – 5242
2024
Q3 		– Sell
-1,171
Closed -$17.7K – 5344
2024
Q2 		$26.1K Sell
1,171
-1,408
-55% -$43.5K ﹤0.01% 4391
2024
Q1 		$152K Sell
2,579
-6,838
-73% -$295K ﹤0.01% 4251
2023
Q4 		$209K Buy
9,417
+8,285
+732% +$125K ﹤0.01% 4399
2023
Q3 		$24.4K Sell
1,132
-6,498
-85% -$255K ﹤0.01% 4131
2023
Q2 		$515K Buy
7,630
+803
+12% +$332K ﹤0.01% 2741
2023
Q1 		$3.18M Sell
6,827
-1,273
-16% -$674K ﹤0.01% 1853
2022
Q4 		$3.24M Buy
8,100
+333
+4% +$128K ﹤0.01% 1922
2022
Q3 		$2.53M Buy
7,767
+7,591
+4,313% +$2.44M ﹤0.01% 1591
2022
Q2 		$46K Sell
176
-399
-69% -$102K ﹤0.01% 4066
2022
Q1 		$173K Sell
575
-3,606
-86% -$1.26M ﹤0.01% 3506
2021
Q4 		$1.47M Buy
4,181
+2,737
+190% +$852K ﹤0.01% 2570
2021
Q3 		$369K Buy
1,444
+985
+215% +$349K ﹤0.01% 3335
2021
Q2 		$306K Sell
459
-3,436
-88% -$1.98M ﹤0.01% 3347
2021
Q1 		$3.38M Buy
3,895
+2,293
+143% +$2.44M ﹤0.01% 1853
2020
Q4 		$1.49M Sell
1,602
-489
-23% -$514K ﹤0.01% 2477
2020
Q3 		$2.15M Sell
2,091
-344
-14% -$370K ﹤0.01% 2033
2020
Q2 		$2.47M Sell
2,435
-3,187
-57% -$2.96M ﹤0.01% 1916
2020
Q1 		$4.88M Sell
5,622
-1,930
-26% -$1.92M ﹤0.01% 1489
2019
Q4 		$8.1M Buy
7,552
+1,395
+23% +$1.42M ﹤0.01% 1562
2019
Q3 		$5.69M Sell
6,157
-80
-1% -$87.9K ﹤0.01% 1741
2019
Q2 		$7.04M Buy
6,237
+4,218
+209% +$4.62M ﹤0.01% 1575
2019
Q1 		$2.74M Buy
2,019
+1,731
+601% +$2.35M ﹤0.01% 2231
2018
Q4 		$333K Sell
288
-1,350
-82% -$1.52M ﹤0.01% 4188
2018
Q3 		$2.49M Buy
1,638
+1,419
+648% +$2.19M ﹤0.01% 2623
2018
Q2 		$342K Sell
219
-773
-78% -$1.01M ﹤0.01% 4278
2018
Q1 		$1.15M Buy
992
+473
+91% +$623K ﹤0.01% 3042
2017
Q4 		$616K Buy
519
+445
+601% +$558K ﹤0.01% 3584
2017
Q3 		$99K Buy
74
+24
+48% +$25.3K ﹤0.01% 4948
2017
Q2 		$40K Sell
50
-264
-84% -$184K ﹤0.01% 5471
2017
Q1 		$195K Sell
314
-166
-35% -$101K ﹤0.01% 4352
2016
Q4 		$256K Buy
480
+407
+558% +$203K ﹤0.01% 4000
2016
Q3 		$38K Buy
+73
New +$34.4K ﹤0.01% 5139
2016
Q2 		– Sell
-113
Closed -$59K – 6398
2016
Q1 		$59K Buy
113
+63
+126% +$31.4K ﹤0.01% 4667
2015
Q4 		$37K Buy
50
+38
+317% +$25.2K ﹤0.01% 4955
2015
Q3 		$6K Sell
12
-27
-69% -$16.4K ﹤0.01% 5978
2015
Q2 		$22K Buy
39
+28
+255% +$16.3K ﹤0.01% 5618
2015
Q1 		$8K Sell
11
-10
-48% -$7.75K ﹤0.01% 6343
2014
Q4 		$14K Buy
+21
New +$13.5K ﹤0.01% 6519

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Barclays's KYNB Position: Q2 2025 in Review

Barclays held its Kyntra Bio (KYNB) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5360.

Barclays first reported a position in KYNB in Q4 2014 and has held it in 38 quarters since. The position peaked at $8.1M in Q4 2019. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Barclays held 0 shares of Kyntra Bio worth $0 as of Q2 2025.
  • Barclays left its Kyntra Bio share count unchanged in Q2 2025.
  • Kyntra Bio made up ﹤0.01% of Barclays's portfolio in Q2 2025, its #5360 holding.
  • Barclays first reported a position in Kyntra Bio in Q4 2014 and has held it in 38 quarters since.
  • Barclays's Kyntra Bio position peaked at $8.1M in Q4 2019.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.